“Increasing Adoption of Liquid Biopsy Techniques”
- One prominent trend in the global molecular diagnostics market is the increasing adoption of liquid biopsy techniques
- This trend is driven by the growing demand for non-invasive diagnostic methods, the need for real-time monitoring of disease progression, and the rising emphasis on personalized treatment strategies, particularly in oncology
- For instance, companies such as Guardant Health and Biocept are advancing liquid biopsy technologies that analyze circulating tumor DNA (ctDNA) and other biomarkers to enable early cancer detection and therapy selection
- The continued shift toward minimally invasive procedures, along with technological improvements in biomarker detection and genomic analysis, is accelerating the integration of liquid biopsy into routine clinical practice
- As healthcare systems focus on precision medicine, early diagnosis, and improved patient outcomes, liquid biopsy is expected to play a transformative role in expanding access to timely, accurate, and personalized diagnostics across various disease areas
